Hypoglycemic effect on adult zebrafish (Danio rerio) of the 3β-6β-16β-trihydroxylup-20(29)-ene triterpene isolated from Combretum leprosum leaves in vivo and in silico approach
Marnielle Rodrigues Coutinho, Antonio Wlisses da Silva, Maria Kueirislene Amâncio Ferreira, Emanuela de Lima Rebouças, Francisco Rogênio S. Mendes, Edson Holanda Teixeira, Emanuelle Machado Marinho, Márcia Machado Marinho, Emmanuel Silva Marinho, Alexandre Magno Rodrigues Teixeira, Jane Eire Silva Alencar de Menezes, Hélcio Silva dos Santos
{"title":"Hypoglycemic effect on adult zebrafish (Danio rerio) of the 3β-6β-16β-trihydroxylup-20(29)-ene triterpene isolated from Combretum leprosum leaves in vivo and in silico approach","authors":"Marnielle Rodrigues Coutinho, Antonio Wlisses da Silva, Maria Kueirislene Amâncio Ferreira, Emanuela de Lima Rebouças, Francisco Rogênio S. Mendes, Edson Holanda Teixeira, Emanuelle Machado Marinho, Márcia Machado Marinho, Emmanuel Silva Marinho, Alexandre Magno Rodrigues Teixeira, Jane Eire Silva Alencar de Menezes, Hélcio Silva dos Santos","doi":"10.1111/fcp.12776","DOIUrl":null,"url":null,"abstract":"<p>Drugs used to manage type 2 diabetes mellitus cause adverse effects. Therefore, the search for new drugs as an alternative for the treatment of diabetes increases. The effect of triterpene 3β-6β-16β-trihydroxylup-20(29)-ene isolated from the leaves of <i>C. leprosum</i> (CLF-1) on sucrose-induced hyperglycemia in adult zebrafish (<i>Danio rerio</i>) was evaluated. Initially, adult zebrafish (<i>n</i> = 6/group) underwent hyperglycemia induction by sucrose at 83.25 mM/L for 7 days by immersion. The hyperglycemic groups were treated with CLF-1 (4, 20, and 40 mg/kg), metformin (200 mg/kg), and acarbose (300 mg/kg) for 4 days. The in silico interaction of CLF-1, metformin, and acarbose with the enzyme maltase-glucoamylase (CtMGAM) was investigated. CLF-1 reduced sucrose-induced hyperglycemia after 4 days of treatment, in addition to having better affinity energy with CtMGAM than metformin and acarbose. Thus, CLF-1 may be a new pharmacological alternative as a hypoglycemic agent for the treatment of diabetes.</p>","PeriodicalId":12657,"journal":{"name":"Fundamental & Clinical Pharmacology","volume":null,"pages":null},"PeriodicalIF":2.1000,"publicationDate":"2022-03-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Fundamental & Clinical Pharmacology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/fcp.12776","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 2
Abstract
Drugs used to manage type 2 diabetes mellitus cause adverse effects. Therefore, the search for new drugs as an alternative for the treatment of diabetes increases. The effect of triterpene 3β-6β-16β-trihydroxylup-20(29)-ene isolated from the leaves of C. leprosum (CLF-1) on sucrose-induced hyperglycemia in adult zebrafish (Danio rerio) was evaluated. Initially, adult zebrafish (n = 6/group) underwent hyperglycemia induction by sucrose at 83.25 mM/L for 7 days by immersion. The hyperglycemic groups were treated with CLF-1 (4, 20, and 40 mg/kg), metformin (200 mg/kg), and acarbose (300 mg/kg) for 4 days. The in silico interaction of CLF-1, metformin, and acarbose with the enzyme maltase-glucoamylase (CtMGAM) was investigated. CLF-1 reduced sucrose-induced hyperglycemia after 4 days of treatment, in addition to having better affinity energy with CtMGAM than metformin and acarbose. Thus, CLF-1 may be a new pharmacological alternative as a hypoglycemic agent for the treatment of diabetes.
期刊介绍:
Fundamental & Clinical Pharmacology publishes reports describing important and novel developments in fundamental as well as clinical research relevant to drug therapy. Original articles, short communications and reviews are published on all aspects of experimental and clinical pharmacology including:
Antimicrobial, Antiviral Agents
Autonomic Pharmacology
Cardiovascular Pharmacology
Cellular Pharmacology
Clinical Trials
Endocrinopharmacology
Gene Therapy
Inflammation, Immunopharmacology
Lipids, Atherosclerosis
Liver and G-I Tract Pharmacology
Metabolism, Pharmacokinetics
Neuropharmacology
Neuropsychopharmacology
Oncopharmacology
Pediatric Pharmacology Development
Pharmacoeconomics
Pharmacoepidemiology
Pharmacogenetics, Pharmacogenomics
Pharmacovigilance
Pulmonary Pharmacology
Receptors, Signal Transduction
Renal Pharmacology
Thrombosis and Hemostasis
Toxicopharmacology
Clinical research, including clinical studies and clinical trials, may cover disciplines such as pharmacokinetics, pharmacodynamics, pharmacovigilance, pharmacoepidemiology, pharmacogenomics and pharmacoeconomics. Basic research articles from fields such as physiology and molecular biology which contribute to an understanding of drug therapy are also welcomed.